Rashmi Murthy

11PUBLICATIONS
106CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 19, 2026
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results.

Rashmi K Murthy, Barbara J O'Brien, Donald A Berry

|Jan 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.

Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava

|Oct 02, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.

Clinton Yam, Miral Patel, Holly A Hill

|Dec 15, 2023
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations.

Fatma Nihan Akkoc Mustafayev, Mihir Amitabh Shukla, Amanda Lanier

|Oct 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.

Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita

|Sep 08, 2022
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases.

Sheheryar Kabraji, Jing Ni, Sarah Sammons

Pageof 2

Frequent Collaborators

5 joint publications

Debu Tripathy

3 joint publications

Akshara Singareeka-Raghavendra

3 joint publications

Gabriel N Hortobagyi

3 joint publications

Jason White